Resources Contact Us Home
Browse by: INVENTOR PATENT HOLDER PATENT NUMBER DATE
 
 
Memory Pharmaceuticals Corporation Patents
Assignee:
Memory Pharmaceuticals Corporation
Address:
Montvale, NJ
No. of patents:
31
Patents:












Patent Number Title Of Patent Date Issued
8273891 Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, pyrazolopyridines, isothiazolopyri September 25, 2012
The present invention relates generally to the field of ligands for nicotinic acetylcholine receptors (nACh receptors), activation of nACh receptors, and the treatment of disease conditions associated with defective or malfunctioning nicotinic acetylcholine receptors, especially of t
8263619 Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, and preparation and uses thereof September 11, 2012
The present invention relates generally to the field of ligands for nicotinic acetylcholine receptors (nACh receptors), activation of nACh receptors, and the treatment of disease conditions associated with defective or malfunctioning nicotinic acetylcholine receptors, especially of t
8252811 Indazoles, benzothiazoles, and benzoisothiazoles, and preparation and uses thereof August 28, 2012
The present invention relates generally to the field of ligands for nicotinic acetylcholine receptors (nAChR), activation of nAChRs, and the treatment of disease conditions associated with defective or malfunctioning nicotinic acetylcholine receptors, especially of the brain. Further
8158629 Indoles, 1H-indazoles, 1,2-benzisoxazoles, and 1,2-benzisothiazoles, and preparation and uses th April 17, 2012
The present invention relates generally to the field of ligands for nicotinic acetylcholine receptors (nAChR), activation of nAChRs, and the treatment of disease conditions associated with defective or malfunctioning nicotinic acetylcholine receptors, especially of the brain. Further
8134003 Indazoles, benzothiazoles, and benzoisothiazoles, and preparation and uses thereof March 13, 2012
The present invention relates generally to the field of ligands for nicotinic acetylcholine receptors (nAChR), activation of nAChRs, and the treatment of disease conditions associated with defective or malfunctioning nicotinic acetylcholine receptors, especially of the brain. Further
8106066 Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, pyrazolopyridines, isothiazolopyri January 31, 2012
The present invention relates generally to the field of ligands for nicotinic acetylcholine receptors (nACh receptors), activation of nACh receptors, and the treatment of disease conditions associated with defective or malfunctioning nicotinic acetylcholine receptors, especially of t
7994199 Heterocyclic compounds, methods for the preparation thereof, and uses thereof August 9, 2011
The compounds of the present invention are of formula I: ##STR00001## wherein A, R.sup.3, R.sup.4 is as defined herein, are useful as ligands for nicotinic receptors.
7964600 Indoles, 1H-indazoles, 1,2-benzisoxazoles, and 1,2-benzisothiazoles, and preparation and uses th June 21, 2011
The present invention relates generally to the field of ligands for nicotinic acetylcholine receptors (nAChR), activation of nAChRs, and the treatment of disease conditions associated with defective or malfunctioning nicotinic acetylcholine receptors, especially of the brain. Further
7943773 Indazoles, benzothiazoles, and benzoisothiazoles, and preparation and uses thereof May 17, 2011
The present invention relates generally to the field of ligands for nicotinic acetylcholine receptors (nAChR), activation of nAChRs, and the treatment of disease conditions associated with defective or malfunctioning nicotinic acetylcholine receptors, especially of the brain. Further
7932248 1H-indazoles, benzothiazoles, 1,2-benzoisoxazoles, 1,2-benzoisothiazoles, and chromones and prep April 26, 2011
The present invention relates generally to the field of ligands for nicotinic acetylcholine receptors (nAChR), activation of nAChRs, and the treatment of disease conditions associated with defective or malfunctioning nicotinic acetylcholine receptors, especially of the brain. Further
7902217 Indoles, 1H-indazoles, 1,2-benzisoxazoles, 1,2-benzoisothiazoles, and preparation and uses there March 8, 2011
The present invention relates generally to the field of ligands for nicotinic acetylcholine receptors (nACh receptors), activation of nACh receptors, and the treatment of disease conditions associated with defective or malfunctioning nicotinic acetylcholine receptors, especially of t
7790722 Indoles, 1H-indazoles, 1,2-benzisoxazoles, and 1,2-benzisothiazoles, and preparation and uses th September 7, 2010
The present invention relates generally to the field of ligands for nicotinic acetylcholine receptors (nAChR), activation of nAChRs, and the treatment of disease conditions associated with defective or malfunctioning nicotinic acetylcholine receptors, especially of the brain. Further
7723348 Phosphodiesterase 4 inhibitors May 25, 2010
Selective PDE4 inhibition is achieved by aryl and heteroaryl pyrazole compounds. The compounds exhibit improved PDE4 inhibition as compared to compounds such as rolipram and show selectivity with regard to inhibition of other classes of PDEs.
7700631 Phosphodiesterase 4 inhibitors April 20, 2010
PDE4 inhibition is achieved by novel nitroxide compounds, e.g., N-substituted aniline and diphenylamine analogs. The compounds of the present invention are of Formulas I-III: ##STR00001## wherein A, B, D, R.sup.1, R.sup.2, R.sup.3, R.sup.7, R.sup.8, R.sup.9, R.sup.10 and R.sup.6 are
7700630 Heterocyclic compounds, methods for the preparation thereof, and uses thereof April 20, 2010
The compounds of the present invention are of formula I: ##STR00001## wherein A, R.sup.3, R.sup.4 is as defined herein, are useful as ligands for nicotinic receptors.
7696229 Compounds having 5-HT6 receptor affinity April 13, 2010
The present disclosure provides compounds having affinity for the 5HT6 receptor which are of the formula (I): ##STR00001## wherein R.sup.1-R.sup.3 A, B, D, E, G, Q, and x are as defined herein. The disclosure also relates to methods of preparing such compounds, compositions containi
7696198 Phosphodiesterase 4 inhibitors April 13, 2010
Selective PDE4 inhibition is achieved by 4-(substituted-phenyl)-2-pyrrolidinone compounds. The compounds exhibit improved PDE4 inhibition as compared to compounds like rolipram and show selectivity with regard to inhibition of other classes of PDEs. The compounds of the present inven
7655802 Phosphodiesterase 4 inhibitors, including aminoindazole and aminobenzofuran analogs February 2, 2010
PDE4 inhibition is achieved by novel compounds, e.g., aminoindazole and aminobenzofuran analogs. The compounds of the present invention are of Formulas I and II: ##STR00001## wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.7 and R.sup.8 are as defined herein.
7632831 1H-indazoles, benzothiazoles, 1,2-benzoisoxazoles, 1,2-benzoisothiazoles, and chromones and prep December 15, 2009
The present invention relates generally to the field of ligands for nicotinic acetylcholine receptors (nAChR), activation of nAChRs, and the treatment of disease conditions associated with defective or malfunctioning nicotinic acetylcholine receptors, especially of the brain. Further
7625924 Nicotinic alpha-7 receptor ligands and preparation and uses thereof December 1, 2009
The present invention relates generally to the field of ligands for nicotinic acetylcholine receptors (nAChR), activation of nAChRs, and the treatment of disease conditions associated with defective or malfunctioning nicotinic acetylcholine receptors, especially of the brain. Further
7585882 Phosphodiesterase 4 inhibitors September 8, 2009
Selective PDE4 inhibition is achieved by novel compounds, e.g., 4-(substituted-phenyl)-2-pyrrolidinone compounds. The compounds of the present invention are of formula I: ##STR00001## wherein R.sup.1, R.sup.2, and R.sup.3 are as defined herein. The disclosure also relates to methods
7576080 Certain thienopyrimidine derivatives as phosphodiesterase 10 inhibitors August 18, 2009
Certain thienopyrimidine derivatives are useful for the inhibition of PDE10 enzymes, and thus are useful for treating psychiatric or neurological syndromes, e.g., pyschoses, obsessive-compulsive disorder and/or Parkinson's disease, as well as, for example, treating a disease state mo
7495017 Phosphodiesterase 4 inhibitors February 24, 2009
Selective PDE4 inhibition is achieved by aryl and heteroaryl pyrazole compounds. The compounds exhibit improved PDE4 inhibition as compared to compounds such as rolipram and show selectivity with regard to inhibition of other classes of PDEs.
7432266 Phosphodiesterase 4 inhibitors October 7, 2008
Selective PDE4 inhibition is achieved by aryl and heteroaryl pyrazole compounds. The compounds exhibit improved PDE4 inhibition as compared to compounds such as rolipram and show selectivity with regard to inhibition of other classes of PDEs.
7429664 Indazoles, benzothiazoles, and benzoisothiazoles, and preparation and uses thereof September 30, 2008
The present invention relates generally to the field of ligands for nicotinic acetylcholine receptors (nAChR), activation of nAChRs, and the treatment of disease conditions associated with defective or malfunctioning nicotinic acetylcholine receptors, especially of the brain. Further
7405230 Phosphodiesterase 4 inhibitors, including N-substituted aniline and diphenylamine analogs July 29, 2008
PDE4 inhibition is achieved by novel compounds, e.g., N-substituted aniline and diphenylamine analogs. The compounds of the present invention are of Formula I: ##STR00001## wherein R.sup.1, R.sup.2, R.sup.3 and R.sup.4 are as defined herein.
7396833 Indoles, 1H-indazoles, 1,2-benzisoxazoles, and 1,2-benzisothiazoles, and preparation and uses th July 8, 2008
The present invention relates generally to the field of ligands for nicotinic acetylcholine receptors (nAChR), activation of nAChRs, and the treatment of disease conditions associated with defective or malfunctioning nicotinic acetylcholine receptors, especially of the brain. Further
7358057 QM-7 and QT-6 cells transfected with mutant cell surface expressed channel receptors and assays April 15, 2008
The present invention relates e.g., to QM-7 or QT-6 cells comprising a heterologous mutant nicotinic .alpha.7 acetylcholine receptor and/or a nucleic acid encoding it, or a fragment or variant thereof. In a preferred embodiment, the mutant nicotinic .alpha.7 acetylcholine receptor su
7335654 Phosphodiesterase 4 inhibitors February 26, 2008
PDE4 inhibition is achieved by novel compounds of the Formula I: ##STR00001## wherein R.sup.1 and R.sup.2 are as defined herein.
7153871 Phosphodiesterase 4 inhibitors, including aminoindazole and aminobenzofuran analogs December 26, 2006
PDE4 inhibition is achieved by novel compounds, e.g., aminoindazole and aminobenzofuran analogs. The compounds of the present invention are of Formulas I and II: ##STR00001## wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.7 and R.sup.8 are as defined herein.
7087625 Phosphodiesterase 4 inhibitors August 8, 2006
PDE4 inhibition is achieved by novel nitroxide compounds, e.g., N-substituted aniline and diphenylamine analogs. The compounds of the present invention are of Formulas I III: ##STR00001## wherein A, B, D, R.sup.1, R.sup.2, R.sup.3, R.sup.7, R.sup.8, R.sup.9, R.sup.10 and R.sup.6are

 
 
  Recently Added Patents
Stock analysis method, computer program product, and computer-readable recording medium
Compound semiconductor epitaxial structure and method for fabricating the same
Polishing composition
Chair
Stool
Method and device for detecting the dysfunction of a gas pressure sensor in a vehicle tire
Qualification screening system and screening method thereof, qualification screening device and device under qualification screening
  Randomly Featured Patents
Sense amplifier architecture for content addressable memory device
Epitaxial magnesium oxide as a buffer layer on (111) tetrahedral semiconductors
Puller
Utility cart
Stable flavor-containing dentifrice
Silver halide color photographic light-sensitive material and image forming method
Article of jewelry
Fiber-optic vibration sensor based on frequency modulation of light-excited oscillators
Apparatus for separating isotopes of uranium
Reverse eccentric double parallel pressure seal business form